Age Reversal Technology
Age Reversal Technology (2026 Snapshot)
Note: The categories below reflect a practical, current view of what’s in real-world use vs. what’s still experimental. “Age reversal” is often used loosely; most items here are better described as healthspan optimization or biological age modulation rather than proven whole-body age reversal in humans.
Tier 1 — Evidence-Based Longevity Modulation (Best-supported today)
- Exercise (especially resistance training)
Improves strength, metabolic health, cardiovascular function, and resilience. Strongest real-world “longevity intervention” overall. - Nutrition strategies (caloric restriction principles, protein strategy, fasting frameworks)
Supports metabolic health, body composition, and may influence longevity pathways (varies by protocol and individual). - mTOR modulation / Autophagy support
Includes lifestyle approaches (fasting) and drug-research approaches. A major longevity pathway with strong animal evidence. - Inflammation control (“inflammaging” reduction)
Targets chronic low-grade inflammation through lifestyle + medical management of risk factors. - Sleep and circadian optimization
Foundational for hormone regulation, cognition, metabolic control, and recovery. - Metabolic control (insulin sensitivity, body fat management, cardio-respiratory fitness)
A core pillar for reducing age-related disease risk and improving healthspan.
Tier 2 — In Human Trials / Serious Development (Promising, not “proven reversal”)
- Senolytics
Drugs/supplements aimed at clearing senescent cells (e.g., dasatinib + quercetin in research contexts). Early human trials exist; no broad clinical “aging” approval. - Rapamycin / mTOR inhibitors (longevity research)
Longstanding clinical use in other contexts; being explored for immune/aging-related outcomes. Still not an approved “anti-aging” therapy. - Stem cell therapy (regenerative medicine)
Used for select orthopedic/repair contexts; systemic rejuvenation claims exceed evidence in many commercial settings. - Plasma exchange / plasma dilution approaches
Inspired by “young blood” animal work, shifting toward safer exchange/dilution concepts. Still early for longevity endpoints. - NAD+ support (NMN, NR, related pathways)
May improve certain metabolic markers; definitive human anti-aging outcomes are not established. - Microbiome manipulation
Diet, pre/probiotics, and investigational approaches; longevity claims remain emergent and individualized. - Mitochondrial-targeted therapies (developmental)
A growing area aimed at energy function and resilience; still developing for longevity outcomes. - Thymus/immune rejuvenation approaches
Early research suggests immune function may be modifiable; longevity implications still under investigation.
Tier 3 — Experimental / High-Risk (Closest to “true reset” ideas, but not ready)
- Epigenetic reprogramming (partial reprogramming / Yamanaka-factor-inspired)
Aims to reset epigenetic age markers. Strong animal research interest; human safety, dosing, and cancer risk are key barriers. - Gene therapy for aging mechanisms
Gene therapies are real for specific diseases; using them systemically for aging is still experimental and complex. - Telomerase activation
Theoretical rejuvenation appeal but meaningful cancer-risk and control challenges remain. - CRISPR-based systemic gene editing for aging
Powerful for specific corrections, but broad anti-aging use faces delivery, targeting, safety, and ethics hurdles.